Chamberlain University
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
,Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative effect metabolism (CYP NT)
Potency (if noted. receptor occupancy if noted ) 450 enzyme)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target symptoms: Half-Life: • Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and Haldol • Akathisia
vocal utterances in Tourette’s Syndrome Second- decanoate: • Drug-induced parkinsonism
line treatment of severe behavior problems in approximately • Tardive dyskinesia, dystonia
children of combative, explosive, 3 • Irreversible involuntary dyskinetic
hyperexcitability Second- line short-term movements
weeks Oral: 12-
treatment of hyperactive children Treatment of • Galactorrhea, amenorrhea •
38 hours
schizophrenic patients who require prolonged Dizziness, sedation
parenteral antipsychotic therapy Bipolar Disorder • Dry mouth
Metabolism:
• Constipation
Behavioral disturbances in dementias Delirium CYP1A2,
• Urinary retention
(with lorazepam) Positive symptoms of psychosis, CYP2D6, • Blurred vision
violent or aggressive behavior CYP3A4 • Decreased sweating
Potency: High potency first-generation • Hypotension
Neurotransmitter(s) affected: • Tachycardia
Blocks dopamine 2 receptors, reducing positive • Hypertension
symptoms of psychosis and combative, explosive, • Weight gain
and hyperactive behaviors Blocks dopamine 2
receptors in the nigrostriatal pathway, improving
tics and other symptoms in Tourette’s syndrome
Thioridazine Target symptoms: Used for Schizophrenia in Half-Life: 21-24 • Neuroleptic-induced deficit syndrome
patients who fail to respond to treatment with hours • Akathisia
other antipsychotic drugs Positive symptoms of • Priapism
psychosis Metabolism: • Drug-induced parkinsonism
Motor and autonomic hyperactivity Violent or CYP450 2D6 • Tardive dyskinesia
• Irreversible involuntary dyskinetic
aggressive behavior
movements
Potency: Low-potency first-generation
• Galactorrhea, amenorrhea
Neurotransmitter(s) affected: Blocks dopamine 2
receptors, reducing positive symptoms of psychosis • Pigmentary retinopathy
Downloaded by Benjamin Luca ()
, • Dizziness, sedation
Downloaded by Benjamin Luca ()
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
,Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative effect metabolism (CYP NT)
Potency (if noted. receptor occupancy if noted ) 450 enzyme)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target symptoms: Half-Life: • Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and Haldol • Akathisia
vocal utterances in Tourette’s Syndrome Second- decanoate: • Drug-induced parkinsonism
line treatment of severe behavior problems in approximately • Tardive dyskinesia, dystonia
children of combative, explosive, 3 • Irreversible involuntary dyskinetic
hyperexcitability Second- line short-term movements
weeks Oral: 12-
treatment of hyperactive children Treatment of • Galactorrhea, amenorrhea •
38 hours
schizophrenic patients who require prolonged Dizziness, sedation
parenteral antipsychotic therapy Bipolar Disorder • Dry mouth
Metabolism:
• Constipation
Behavioral disturbances in dementias Delirium CYP1A2,
• Urinary retention
(with lorazepam) Positive symptoms of psychosis, CYP2D6, • Blurred vision
violent or aggressive behavior CYP3A4 • Decreased sweating
Potency: High potency first-generation • Hypotension
Neurotransmitter(s) affected: • Tachycardia
Blocks dopamine 2 receptors, reducing positive • Hypertension
symptoms of psychosis and combative, explosive, • Weight gain
and hyperactive behaviors Blocks dopamine 2
receptors in the nigrostriatal pathway, improving
tics and other symptoms in Tourette’s syndrome
Thioridazine Target symptoms: Used for Schizophrenia in Half-Life: 21-24 • Neuroleptic-induced deficit syndrome
patients who fail to respond to treatment with hours • Akathisia
other antipsychotic drugs Positive symptoms of • Priapism
psychosis Metabolism: • Drug-induced parkinsonism
Motor and autonomic hyperactivity Violent or CYP450 2D6 • Tardive dyskinesia
• Irreversible involuntary dyskinetic
aggressive behavior
movements
Potency: Low-potency first-generation
• Galactorrhea, amenorrhea
Neurotransmitter(s) affected: Blocks dopamine 2
receptors, reducing positive symptoms of psychosis • Pigmentary retinopathy
Downloaded by Benjamin Luca ()
, • Dizziness, sedation
Downloaded by Benjamin Luca ()
